Syneos Health, Fosun Pharma USA Partner to Launch Serplulimab
For the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer in the United States, Syneos Health, the only fully integrated biopharmaceutical solutions organization, has announced a strategic partnership with Fosun Pharma USA Inc., the US-based subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd. Syneos Health will provide Full-Service Commercial support […]
Continue Reading